PUBLIC COMPANY
save$SUPNSUPERNUS PHARMACEUTICALS, INC.
$SUPN47.45-2.25%Rockville, MD, USupdated 9h ago
community read0 votes
pipeline
3
marketed
2
phase 3
0
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 22Marketed
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase3Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
- phase2Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
- phase4Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
- phase2Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- phase4Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- phase4Therapy for Migraine Prevention in Children 6-11 Years of Age
- phase3A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
- phase2Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 18, 26SELLBhatt Padmanabh P.· Sr. VP of IP, CSO−$339K↗
- Mar 18, 26SELLBhatt Padmanabh P.· Sr. VP of IP, CSO−$21K↗
- Mar 17, 26SELLBhatt Padmanabh P.· Sr. VP of IP, CSO−$1.38M↗
- Mar 17, 26SELLBhatt Padmanabh P.· Sr. VP of IP, CSO−$1.13M↗
- Mar 16, 26SELLBhatt Padmanabh P.· Sr. VP of IP, CSO−$1.71M↗
- Mar 16, 26SELLBhatt Padmanabh P.· Sr. VP of IP, CSO−$802K↗
- Mar 13, 26SELLKhattar Jack A.· President, CEO−$1.21M↗
- Mar 13, 26SELLKhattar Jack A.· President, CEO−$548K↗
- Mar 13, 26SELLKhattar Jack A.· President, CEO−$6K↗
- Mar 12, 26SELLHudson Frederick M.· −$272K↗
- Mar 10, 26SELLHorich William Todd· SVP, Commercial Operations−$244K↗
- Mar 9, 26SELLHorich William Todd· SVP, Commercial Operations−$240K↗
- Mar 9, 26SELLMottola Frank· SVP, Chief Tech. Ops. Officer−$87K↗
- Mar 6, 26SELLGEMAYEL GEORGES· −$466K↗
- Mar 5, 26SELLGEMAYEL GEORGES· −$537K↗
routine RSU / option mechanics (5)
- Mar 18, 26option exerciseBhatt Padmanabh P. · Sr. VP of IP, CSO7,250 sh
- Mar 18, 26option exerciseBhatt Padmanabh P. · Sr. VP of IP, CSO7,250 sh
- Mar 17, 26option exerciseBhatt Padmanabh P. · Sr. VP of IP, CSO22,750 sh
- Mar 17, 26option exerciseBhatt Padmanabh P. · Sr. VP of IP, CSO15,000 sh
- Mar 17, 26option exerciseBhatt Padmanabh P. · Sr. VP of IP, CSO12,250 sh
🐶 Hiring Signal
next earnings Nov 3, 2026
News
- Supernus and Indivior merge to create CNS mega-company with 11 approved drugsSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”biospace · 17d ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that